J&J Dodges Claims In 2nd Philly Risperdal Trial

Law360, Philadelphia (March 20, 2015, 2:26 PM EDT) -- A Johnson & Johnson unit notched a victory Friday after a Philadelphia jury cleared the company of liability in a case alleging that it had failed to warn the doctors of a boy who took the antipsychotic drug Risperdal about the risks of female breast growth.

The verdict came after a monthlong trial in the Philadelphia County Court of Common Pleas, in which the jury heard evidence that Janssen Pharmaceuticals Inc. had worked for years to obscure evidence that the drug was linked to growth of female breast tissue — a condition known as gynecomastia — in adolescent boys.

Janssen argued...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!